drugset / Trial / NCT00318994

Evaluation of Pancreatic Tissue Penetration of Meronem® in the Prophylaxis of Septic Complications in Severe Pancreatitis

NCT00318994

Phase 4 Completed 6 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To measure meropenem pancreatic tissue penetration in subjects with severe pancreatitis requiring surgery between 30 to 60 minutes after a bolus of 1 g IV meropenem given during the induction period of anesthesia.

Timeline

Start
2002-02
Primary completion
2005-09
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Meropenem Small molecule 1 g Intravenous

Indications